Genetic susceptibility to Andes Hantavirus: Association between severity of disease and HLA alleles in Chilean patients;Susceptibilidad genética a hantavirus Andes: Asociación entre la expresión clínica de la infección y alelos del sistema HLA en pacientes chilenos

Revista Chilena de Infectologia

Volumn 24, Issue 5, 2007, Pages 351-359

  Ferrer C , Pablo ^a   Vial C , Pablo A ^b   Ferrés G , Marcela ^c   Godoy M , Paula ^c   Cuiza V , Analia ^b   Marco C , Claudia ^b   Castillo H , Constanza ^d   Umaña C , María Elena ^e   Rothhammer E , Francisco ^a,f   Llop Romero, Elena ^a  

^a UNIVERSITY OF CHILE   (Chile)

^b UNIVERSIDAD DEL DESARROLLO   (Chile)

^c PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^d UNIVERSIDAD DE LA FRONTERA   (Chile)

^e Secretaría Regional Ministerial Octava Región   (Chile)

^f UNIVERSIDAD DE TARAPACÁ   (Chile)

Author keywords

Andes hantavirus; Genetic susceptibility; Hantavirus cardiopulmonary syndrome (HCPS); HLA

Indexed keywords

HLA ANTIGEN;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CHILD; CHILE; FEMALE; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; HOSPITALIZATION; HUMAN; MALE; METHODOLOGY; MIDDLE AGED; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; VIROLOGY; VIRUS INFECTION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHILD; CHILD, PRESCHOOL; CHILE; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HANTAVIRUS INFECTIONS; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX;

EID: 36249018472     PISSN: 07161018     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Sotomayor V. Hantavirus. El Vigía. Boletín de Vigilancia en Salud Pública de Chile 2005; 8: 38-40.
2. Frank S, Jeffrey J. The probability of severe disease in zoonotic and commensal infections. Proc R Soc Lond B 2001; 268: 53-60.
3. Toro J, Vega J, Khan A, Mills J, Padula P, Terry W, et al. An outbreak of hantavirus pulmonary syndrome, Chile, 1997. Emerg Infect Dis 1998; 4: 687-94.
4. Tischler N, Fernández J, Müller I, Martínez R, Galeno H, Villagra E, et al. Complete sequence of genome of the human isolate of Andes virus CHI-7913: comparative sequence and protein structure analysis. Biol Res 2003; 36: 201-10.
5. Spotorno A, Palma E, Valladares J. Biología de roedores reservorios de hantavirus en Chile. Rev Chil Infect 2003; 17: 197-210.
6. Murúa R, Navarrete M, Cádiz R, Figueroa R, Padula P, Zaror L, et al. Síndrome pulmonar por hantavirus: Situación de los roedores reservorios y la población humana en la Décima Región, Chile. Rev Méd Chile 2003; 131: 169-76.
7. Encuesta Nacional de Salud Chile 2003. Enfermedades Transmisibles: Prevalencia de virus de hepatitis, hantavirus y virus papiloma humano (Informe corregido). Disponible en http://epi.minsal.cl/html/invest/ENS/ENS.
8. Castillo C, Naranjo L, Ossa G. Síndrome cardiopulmonar por hantavirus en 21 adultos en la IX Región de Chile. Rev Chil Infect 2000; 17: 241-7.
9. Riquelme R, Riquelme M, Torres A, Rioseco M, Vergara J, Scholz L. et al. Hantavirus pulmonary syndrome in southern Chile. Emerg Infect Dis 2003; 9: 1438-43.
10. Ferres M, Vial P. Hantavirus infection in children. Curr Opin Pediatr 2004; 16: 70-5.
11. Boletín Epidemiológico de Hantavirus. Situación al 25 agosto de 2006, MINSAL: http://epi.minsal.cl/epi/html/bolets/reportes/ Hantavirus/Hantavirus.pdf.
12. Villar J, Maca-Meyer N, Pérez-Méndez L, Flores C. Bench-to-bedside review: Understanding genetic predisposition to sepsis. Crit Care 2004; 8: 180-9.
13. Terajima M, Vapalahti O, Van Epps H, Vaheri A, Ennis F. Immune responses to Puumala virus infection and the pathogenesis of nephropathia epidemica. Microbes Infect 2004; 6: 238-45.
14. Kilpatrick E, Terajima M, Koster F, Catalina M, Cruz J, Ennis F. Role of specific CD8+ T cells in the severity of a fulminant zoonotic viral hemorrhagic fever, Hantavirus Pulmonary Syndrome. J Immunol 2004; 172: 3297-304.
15. Temonen M, Vapalahti O, Holthofer H, Brummer-Korvenkontio M, Vaheri A, Lankinen H. Susceptibility of human cells to Puumala virus infection. J Gen Virol 1993; 74 (Pt 3): 515-8.
16. rd edition, edited by: Specter S, Hodinka R and Young S. ASM Press, Washington DC, USA 2000; 568-78.
17. Hooper J, Larsen T, Custer M, Schmaljohn C. A lethal disease model for hantavirus pulmonary syndrome. Virology 2001; 289: 6-14.
18. Linderholm M, Ahlm C, Settergren B, Waage A, Tarnvik A. Elevated plasma levels of tumor necrosis factor (TNF)-α soluble TNF receptor, interleukin (IL)-6, and IL-10 in patients with hemorrhagic fever with renal syndrome. J Infect Dis 1996; 173: 38-43.
19. Klingstrôm J, Plyusnin A, Vaheri A, Lundkvist A. Wild-type Puumala hantavirus infection induces cytokines, C-reactive protein, and nitric oxide in cynomolgus macaques. J Virol 2002; 76: 444-9.
20. Mori M, Rothman A, Kurane I, Montoya J, Nolte K, Norman J, et al. High levels of cytokine-producing cells in the lung tissues of patients with fatal hantavirus pulmonary syndrome. J Infect Dis 1999; 179: 295-302.
21. Ennis F, Cruz J, Spiropoulou CF, Waite D, Peters C J, Nichol S T, et al. Hantavirus Pulmonary Syndrome: CD8+ and CD4+ cytotoxic T lymphocytes to epitopes on Sin Nombre virus nucleocapsid protein isolated during acute illness. Virology 1997; 238: 380-90.
22. Van Epps H, Schmaljohn C, Ennis F. Human memory cytotoxic T-lymphocyte (CTL) response to Hantaan virus infection: Identificaction of virus-specific and cross-reactive CD8+ CTL epitopes on nucleocapsid protein. J Virol 1999; 73: 5301-8.
23. Lee KY, Chun E, Kim NY, Seong BL. Characterization of HLA-2.1-restricted epitopes, conserved in both Hantaan and Sin Nombre viruses, in Hantaan virus-infected patients. J Gen Virol 2002; 83: 1131-6.
24. Van Epps H, Tejarima M, Mustonen J, Arstila T, Corey E, Vaheri A, et al. Long-lived memory T lymphocyte responses after hantavirus infection. J Exp Med 2002; 196: 579-88.
25. De Carvalho Nicacio C, Sallberg M, Hultgren C, Lundkvist A. T-helper and humoral response to Puumala hantavirus nucleocapsid protein: identification of T-helper epitopes in a mouse model. J Gen Virol 2001; 82: 129-38.
26. Furusho J K Y. Papel de los genes del complejo principal de histocompatibilidad en los procesos infecciosos. Rev Invest Clin 2000; 52(4): 461-6.
27. Fernándes A, Maciel L, Foss M, Donadi E A. Como entender a associação entre o sistema HLA e as doenças auto-imunes endócrinas. Arq Bras Endocrinol Metab 2003; 47: 601-11.
28. Trowsdale J, Ragoussis J, Campbell R. Map of the human MHC. Immunol Today 1991; 12: 443-6.
29. Marsh S, Parham P, Barber L. The HLA Facts Book. Ed. Academic Press, 2000. London UK.
30. Cooke G, Hill A. Genetic of susceptibility to human infectious disease. Nat Rev Genet 2001; 2: 967-77.
31. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, et al. Genetic susceptibility to severe course of nephropathia epidemica caused by Puumala hantavirus. Kidney International 1996; 49: 217-21.
32. Mustonen J, Partanen J, Kanerva M, Pietila K, Vapalahti O, Pasternack A, et al. Association of HLA B27 with benign clinical course of nephropathia epidemica caused by Puumala hantavirus. Scand J Immunol 1998; 47: 277-9.
33. Mäkela S, Mustonen J, Ala-Houhala I, Hurme M, Partanen J, Vapalahti O, et al. Human leukocyte antigen-B8-DR3 is a more important risk factor for severe Puumala hantavirus infection than the tumor necrosis factor-a (-308) G/A polymorphism. J Infect Dis 2002; 186: 843-6.
34. Mustonen J, Huttunen Np, Partanen J, Baer M, Paakkala A, Vapalahti O, et al. Human leukocyte antigens B8-DRB1*03 in pediatric patients with nephropathia epidemica caused by Puumala hantavirus. Pediatr Infect Dis J 2004; 23: 959-61.
35. Koster F,Vigil J, Olson D, Terajima M, Ennis F, Moehenkamp C, et al. Class I, II and III alleles associated with severe Hantavirus Cardiopulmonary Syndrome in the Southwest US. Am J Trop Med 2001; 65: 152 (Abstr).
36. Klein J, Sato A. The HLA system. N Engl J Med 2000; 343: 702-9.
37. Castillo C, Sanhueza L, Täger M, Muñoz S, Ossa G, Vial P. Seroprevalence of antibodies against hantavirus in 10 communities of the IX Region of Chile where hantavirus infection were diagnosed. Rev Méd Chile 2002; 130: 251-8.
38. Täger M, Vial P, Castillo C, Godoy P, Hjelle B, Ferres M. Hantavirus prevalence in the IX Region of Chile. Emerg Infect Dis 2003; 9: 827-32.
39. Vial P A, Valdivieso F, Ferrés M. Enfermedad por hantavirus en Chile: Epidemiología, cuadro clínico y diagnóstico. En: Manejo del Paciente Crítico con Síndrome Cardiopulmonar por Hantavirus. Ed. Salesianos S.A., 2004; pp 23-44.
40. Lahiri D K, Nurnberger J I. A rapid nonenzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucl Acids Res 1991; 19: 5444.
41. Schneider S, Kueffer J M, Roessli D, Excoffier L. Arlequin (ver 1.1): A software for population genetics data analysis. Genetics and Biometry Laboratory, Geneva, 1997.
42. 2 and the problem of small samples. Mol Biol Evol 1989; 6: 539-45.
43. Cornfield J. A statistical problem arising from retrospective studies. In: Proceedings of the Third Berkley Symposium, 1956; 135-148. Volume IV (Negman, J. ed.). University of California Press, Berkley.
44. Dean A, Dean J, Burton A Dicker R. Epi Info: A general-purpose microcomputer program for public health information system. Am J Prev Med 1991; 7: 178-82. Disponible en http://www.cica.es/epinfo/programa.htm.
45. Rodríguez L, Scagliotti P, Quiroga, T. Antígenos HLA-A, B, C y DR en una población urbana de Santiago, Chile. Rev Méd Chile 1993; 121: 523-9.
46. Llop E, Hirsch S, de la Maza M, Dunout D, Iturriaga H, Silva C, et al. Sistema mayor de histocompatibilidad como factor de riesgo de la enfermedad hepática alcohólica. Rev Méd Chile 1995; 123: 687-93.
47. Llop E, Harb Z, Moreno R, Rothhammer F. Genetic marker variation in coastal populations of Chile. Homo 2002; 53: 170-7.
48. Droguett M A, Oyarzún M J, Alruiz P, Jérez V, Mezzano S, Ardiles L. Human leukocyte antigens in indigenous (Mapuche) people in a regional renal transplantation program in Chile. Transplant Proc 2005; 37: 3367-71.
49. Winchester R, Chen Y, Rose S, Selby J, Borkowsky W. Major histocompatibility complex class II DR alleles DRB1*1501 and those encoding HLA-DR13 are preferentially associated with a diminution in maternally transmitted human immunodeficiency virus 1 infection in different ethnic groups: Determination by an automated sequence-based typing method. Proc Natl Acad Sci 1995; 92: 12374-8.
50. Almarri A, Batchelor J R. HLA and hepatitis B infection. Lancet 1994; 344: 1194-5.
51. Hill A V. The immunogenetics of human infectious disease. Annu Rev Immunol 1998; 16: 593-617.
52. Lechmann M, Schneider E M, Giers G, Kaiser R, Dumoulin F L, Sauerbruch T, et al. Increased frequency of the HLA-DR15 (B1*15011) allele in Germany patients with self-limited hepatitis C virus infection. Eur J Clin Invest 1999; 29: 280-3.
53. Kunstmann E, Hardt C, Treitz H, Suerbaum S, Faller G, Peitz U, et al. In the European population HLA-class II genes are not associated with Helicobacter pylori infection. Eur J Gastroenterol Hepatol 2002; 14: 49-53.
54. Shiina T, Inoko H, Kulski J K. An update of the HLA genomic region, locus information and disease associations. Tissue Antigens 2004; 64: 631-49.
55. Thio C, Thomas D, Karacki P, Gao X, Marti D, Kaslow R, et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003; 77: 12083-7.
56. Cao T, Desombere I, Vanlandschoot P, Salberg M, Leroux-Roels G. Characterization of HLA-DR13-restricted CD4+ T cell epitopes of hepatitis B core antigen with self-limited, acute hepatitis B. J Gen Virol 2002; 83: 3023-33.
57. Brostoff J, Male D, Roitt I. Capítulo 27: Autoinmunidad y enfermedades autoinmunitarias. Capítulo 22: Hipersensibilidad de tipo I. Capítulo 11: Regulación de las respuestas inmunitarias. Inmunología, cuarta edición. Madrid: Harcout Brace; 1997, p.27.1-27.13; p.22.1-22.17; y p.11.1-11.14.